Cannara Biotech – www.shopCBD.com
Cannara Biotech (CSE:LOVE)(FRA:8CB)
Headquartered in Montreal, Cannara Biotech is entering the U.S. THC-CBD market, through a subsidiary, with an on-line e-commerce platform called shopCBD.
“We are taking a leadership role by creating a hub for vendors to showcase their products and consumers to purchase hemp-CBD products in a fast and easy way. We want to become the Amazon of CBD,” – ZOHAR KRIVOROT – CEO and Founder
Highlights
- Zohar Krivorot, president and chief executive officer of Cannara Biotech is a 15-year veteran in the tech and on-line industries.
- Cannara Biotech is building the largest indoor cannabis cultivation facility in Quebec and one of the largest in Canada
- shopcbd.com is a platform that will showcase hemp-CBD retail products including tinctures, oils, capsules, body care, vape cartridges and pet-related CBD infused treats
- The indoor facility offers lower risk of airborne infections, mold/mildew and produces a higher grade of cannabis
- The new e-commerce platform will showcase retail products from hemp-CBD manufacturers for the U.S. consumer market
- shopCBD will provide a user-friendly on-line experience where consumers can purchase, review and compare a variety of CBD products
Trending
- With the recent passing of the 2018 Farm Bill in the U.S., CBD represents an emerging sector with many vendors seeking national reach to U.S. customers.
- The company’s strategy is to offer a wide variety of products from leading CBD brands, with competitive pricing and delivery times across the U.S.
- The rise in popularity for CBD products is driven by consumers seeking natural-based health and wellness solutions to treat various ailments from inflammation, anxiety to insomnia amongst many others.
- The hemp-derived CBD market is expected to reach $22-billion (U.S.) by 2022 according to industry analysts at Brightfield Group.
Alongside the e-commerce, on-line platform, Cannara Biotech will have on-site independent THC and CBD brands, following the adoption of regulations on cannabis-infused edibles and beverages, that will produce and ship from the facility. Cannara Biotech’s facility will be a multi-purpose facility that will cultivate recreational cannabis and produce cannabinoid-infused products including edibles, cosmetics, pet products and beverages. These products will be shipped to stores and retail outlets in Canada and to international markets.
Cannara Biotech went public in Q1 of this year and is being traded on the CSE under the ticker “LOVE” and on the FRA under the ticker “8CB”. As of February 12th, 2019, LOVE closed at .22.
—
Isabelle Arsenault
Media Relations
MomentumPR
- Published in Cannara, Marijuana, Medical Marijuana
Cannara Biotech – Quebec’s largest cultivation facility
Cannara Biotech (CSE:LOVE)(FRA:8CB)
Headquartered in Montreal, Cannara Biotech is building the largest indoor cannabis cultivation facility in Quebec and one of the largest in Canada, a modern and secure 625,000-square-foot facility in Farnham, Quebec.
“Being in Quebec allows us to take advantage of the low cost of electricity and gives us a cost advantage over our competitors.” – ZOHAR KRIVOROT – CEO and Founder
Highlights
- Some 100,000 kg of cannabis production is expected per year once all 3 phases are operational. Today, phase 1 is being built with completion expected end of Q2 2019. Once completed, yield is expected at 15,000 kg.
- Cannara Biotech has raised $55M to date, has acquired 19 provisional patents for product exclusivity, and has developed 8 assorted THC/CBD infused product brands to add to their offerings.
- Low electricity cost in Quebec as well as reduced labour cost compared to the rest of Canada gives the Company a cost advantage over their competitors.
- Independent THC and CBD brands will be produced on-site accelerating speed to market.
- The Company will leverage the facility with joint-ventures to produce edibles, pet-products, cosmetics and beverages once the processing license is secured which is estimated for the end of 2019.
- The advantage of growing in an indoor facility offers lower risk of airborne infections, mold/mildew and produces a higher grade of cannabis.
- Cannara Biotech is building an online e-commerce platform (shopCbd.com) that will serve as a podium and distribution channel for US-CBD brands for the American market.
Closer look
Phase 1 will provide 130,000ft2 of growing space. Growing is expected to commence in the fall of 2019 with an estimated yield of 15,000kg.
Cannara Biotech raised $55 million from private investors during the introduction of this project and still have over $40 million in the bank with Phase 1 fully funded.
Phase 2 forecasted to be running by 2020 is 205,000ft2 and likely to yield 38,000kg per year. Phase 3 aiming to be operational in 2022 is 277,000ft2 and expected to produce 55,000kg per year. Cannara Biotech is looking to produce over 100,000kg per year once fully operational.
Currently, 300 sq. ft. space for Phase 2 is being rented by occupants that contribute to a rental revenue of $2 million per year. These earnings pay the monthly fee for the whole facility.
Cannara Biotech’s strategy is also to maximize on the low electricity rates Quebec has with its Hydro and low labour rates in Quebec.
Growing indoor cannabis often results in a higher grade of cannabis. Growing in a controlled environment, protected from many outdoor ailments and mildew creates a more consistent and desirable product for buyers and consumers.
Alongside selling cannabis to intermediaries who will transform the crop into their desired product, Cannara Biotech will have on-site independent THC and CBD brands, following the adoption of regulations on cannabis-infused edibles and beverages, that will produce and ship from the facility. Cannara Biotech’s facility will be a multi-purpose facility that will cultivate recreational cannabis and produce cannabinoid-infused products including edibles, cosmetics, pet products and beverages. These products will be shipped to stores and retail outlets in Canada and to international markets.
Cannara Biotech went public in Q1 of this year and is being traded on the CSE under the ticker “LOVE” and on the FRA under the ticker “8CB”. As of February 12th, 2019, LOVE closed at .22.
—
Isabelle Arsenault
Media Relations
MomentumPR
St-Georges Eco-Mining Subsidiary ZeU Crypto Signs Definitive Agreement with Tiande
Momentum Public Relations
Press Release: February 26 2018
St-Georges Eco-Mining Corp. (CSE: SX) (OTC: SXOOF) (FSE: 85G1) announces that, further to its January 15 and February 8, 2018 press releases, its wholly owned subsidiary ZeU Crypto Networks Inc. has signed a definitive asset purchase agreement dated February 23, 2018 with Qingdao Tiande Technologies Limited and Beijing Tiande Technologies Limited w ith the intervention of Guiyang Tiande Technologies Limited to purchase substantially all the intellectual property of the Vendors.
The following are the material terms of the agreement:
- – ZeU will acquire the Vendor’s intellectual property (including without limitation, all intellectual property and patent applications directly or indirectly related to the Blockchain and smart contract technologies of the Vendors (the ” Blockchain Technology “), including without limitation, BigData, IoB, Sandbox) (the ” IP “)
- – the Vendors will complete: (i) the transfer and successful employment by ZeU of all key employees; (ii) the transfer and assignment of all the IP to ZeU; (iii) the obtaining of all regulatory approvals should they be required; and (iv) the obtaining of all required consents including all consents from clients and collaborators pursuant to the existing contracts of the Vendors (the ” Milestone Conditions “)
- – ZeU, the Vendors and key collaborators will enter into a license agreement and non-competition covenant which will provide, among other things, that ZeU shall irrevocably grant a perpetual , exclusive, transferable and sub-licensable license to the Vendors for use of the Blockchain Technology in China, Hong Kong and Taiwan
- – ZeU will have completed or caused to be completed prior to the Closing Date a debenture financing of not less than $10,000,000 and up to $30,000,000 (the ” Concurrent Financing “)
The purchase price for the Acquisition shall be up to 150,000,000 common shares of ZeU (each a ” Share ” and 150,000,000 Share purchase warrants (each a ” Warrant “) to the Vendors, satisfied by (i) the delivery of a total of 65,000,000 Shares and 75,000,000 Warrants on the closing date of the Acquisition (the ” Closing Date “), (ii) to the extent and only if all of the Milestone Conditions (as defined hereinabove) are satisfied, the delivery of an additional 75,000,000 Shares, within 3 Business Days following the satisfaction of the Milestone Conditions or the Closing Date (whichever is later) and (iii) to the extent and only if twenty (20) new patents pertaining to the Blockchain Technology are issued (the ” Patent Condition “), the delivery of an additional 75,000,000 Shares, within 3 Business Days following the satisfaction of the Patent Condition .
Each Warrant will be exercisable at a price equal to the conversion price pursuant to the Concurrent Financing for a period of three (3) years following the date ZeU completes a transaction pursuant to which its Shares will either be listed on a recognized stock exchange in North America, or will be exchanged for common shares of a reporting issuer listed on a recognized stock exchange in North America.
The agreement was negotiated at arm’s length, and contains customary representations, warranties and closing conditions.
On closing of the Acquisition, Dr. Wei Tek Tsai is to join ZeU’s management as Chief Technology Officer.
The Acquisition remains subject to requisite regulatory approval and satisfaction of closing conditions contained in the agreement.
The Acquisition remains subject to a number of conditions as set forth in the agreement, including (without limitation), the completion of the Concurrent Financing (as defined hereinabove), the receipt of all requisite regulatory approvals and satisfaction of closing conditions contained in the agreement.
ON BEHALF OF THE BOARD OF DIRECTORS
“Frank Dumas”
FRANK DUMAS, PRESIDENT & CEO
About St-Georges
St-Georges is developing new technologies to solve the some of the most common environmental problems in the mining industry.
The Company controls directly or indirectly, through rights of first refusal, all of the active mineral tenures in Iceland. It also explores for nickel on the Julie Nickel Project & for industrial minerals on Quebec’s North Shore and for lithium and rare metals in Northern Quebec and in the Abitibi region. Headquartered in Montreal, St-Georges’ stock is listed on the CSE under the symbol SX, on the US OTC under the Symbol SXOOF and on the Frankfurt Stock Exchange under the symbol 85G1.
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.
- Published in St-Georges Eco-Mining, Uncategorized
Tetra Bio-Pharma names Aphria CFO as Chairman of Audit Committee
Momentum Public Relations
Press Release: February 26, 2018
Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP)(OTCQB:TBPMF), announced changes to its Board of Directors (the “Board”) today, including the appointment of Aphria Inc.’s Chief Financial Officer (CFO), Mr. Carl Merton, as Chair of Tetra’s Audit Committee.
In addition to his extensive financial background, Mr. Merton is a Chartered Accountant and has served as a past Chair of both the CICBV and the International Association of Professional Business Valuators. Mr. Merton is currently a member of the Board of Directors and Chair of the Audit Committee of Motor City Community Credit Union.
Mr. Merton has served on the Tetra Board since 2016 and brings over 20 years of financial and business experience to the Audit Committee. He replaces Mr. Robert Brouillette, whose resignation was accepted immediately upon the Board becoming aware that a decision had been rendered by a professional regulatory organization against Mr. Brouillette in relation to professional activities unrelated to his responsibilities as a director of Tetra.
Mr. André Rancourt, Tetra’s Chair, was also named to the Audit Committee. Mr. Rancourt also acts as a consultant on several commercial strategy committees including FIA and IRZC. He has significant practical experience that provided him with expertise in many fields, including human and animal natural health products. Over the last ten years, he worked as a consultant to re-organize the operations of companies on behalf of several venture capital investment funds.
“These appointments further strengthen our corporate governance practices,” said Tetra CEO Bernard Fortier. “Both Mr. Merton and Mr. Rancourt have stellar reputations in the capital market and will continue to provide our management team and our entire Board with support and guidance as we embark on the next stage of our growth.”
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, failure to obtain sufficient financing to execute the Corporation’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Corporation’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Andre Rancourt
Executive Chairman
andre.r@tetrabiopharma.com
(438) 899-7575
- Published in Tetra Bio Pharma, Uncategorized
MOBI724 Global Solutions Q1 financial release
MOBI724 Global Solutions Q1 financial release – revenues increase by 42{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} in Q1 2017 versus Q1 2016
Momentum Public Relations
Press Release: May 31, 2017
MONTREAL, QUEBEC–(Marketwired – May 31, 2017) – MOBI724 Global Solutions Inc. (MOBI724) (CSE:MOS)(CSE:MOS.CN)(CNSX:MOS)(OTCQB:MOBIF), a FinTech leader offering integrated EMV payment, Card-Linked Offers and Digital Marketing, has filed its Q1 financial results for quarter ending on March 31 2017. MOBI724 is proud to announce that revenues continue to increase in the first quarter. Revenue grew 42{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} to $ 792K in 2017 from $557K in 2016 while our burn rate remains aligned with our business plan.
“These results confirm that we are steadily growing and creating value to our shareholders. In Q1 we confirmed 2 (two) Blue-Sky Opportunities and set the organizational structure to execute our aggressive business plan. Our sales pipeline has grown materially giving us the confidence to execute on the plan for the remainder of the year and beyond” says Marcel Vienneau – CEO.
About MOBI724
MOBI724, a leader in the fintech industry based in Montreal (Canada), offers a unique and fully integrated suite of payment & digital marketing solutions with a combined EMV Payment, Card Linked Offers, and Digital Marketing platform that works on any card and any mobile device. MOBI724’s solutions add value to all types of transactions benefiting banks, retailers and cardholders by leveraging available user and purchasing data to increase transaction volumes and spend. MOBI724 provides a turnkey solution to its clients to capture card transactions on any mobile device, at any point of sale or from any payment card. MOBI724 provides its customers with full and comprehensive traceability and enriched consumer data through its offering. Its solutions enables card associations, retailers, manufacturers, offer providers, mobile operators and card issuers to create, manage, deliver and “track and measure” incentive campaigns worldwide to any mobile device and allow its redemption at any point of sales.
Forward Looking Statements
Certain statements in this document, including those which express management’s expectations or estimations with regard to the Company’s future performance, constitute “forward-looking statements” as understood by applicable securities laws. Forward-looking statements are, of necessity, based on a certain number of estimates and hypotheses; while management considers these to be accurate at the time they are expressed, they are inherently subject to significant uncertainties and risks on the commercial, economic and competitive levels. We advise readers that these forward-looking statements are subject to risks, uncertainties, and other known and unknown factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied in these forward-looking statements. Investors are advised to not rely unduly on the forward-looking statements. This advisory applies to all forward-looking statements, whether expressed orally or in writing, attributed to the Company or to any individual expressing them in the name of the Company. Unless required by law, the Company is under no obligation to publicly update these forward-looking statements, whether to reflect new information, future events, or other circumstances.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
MOBI724 Global Solutions Inc.
Marcel Vienneau
CEO
1-514-394-5200 x 413
www.MOBI724.com
- Published in Financial Technology, Mobi724 Global Solutions, Mobile Technology, News Home, Technology
MOBI724 Global Solutions Announces Initiation of Certification for Local EMV debit cards in the Philippines via its subsidiary MOBI724 Asia
MOBI724 Global Solutions Announces Initiation of Certification for Local EMV debit cards in the Philippines via its subsidiary MOBI724 Asia
Momentum Public Relations
Press Release: May 25, 2017
MONTREAL, QUEBEC–(Marketwired – May 25, 2017) – MOBI724 Global Solutions Inc. (MOBI724) (CSE:MOS)(CSE:MOS.CN)(CNSX:MOS)(OTCQB:MOBIF), a fintech leader offering integrated EMV payment, card-linked offers and digital marketing, via its subsidiary MOBI 724 Asia Inc., today announced the initiation of certification for the local debit EMV schemes in the Philippines market. The certification is on behalf of local prospects who intend to use MOBI724 solutions to roll out a full EMV solution to their customers.
“This certification is expected to boost the reach of MOBI724 in the Philippines and gain access to many acquirers who are transitioning to EMV solutions.”
“We are proud of becoming one of the first local EMV certified end to end solution in the Philippines market which will allow us to serve the Philippines market with the EMV and all our card link solutions which include financial institutions, acquiring networks and merchants alike ” says Marcel Vienneau, CEO, MOBI724. “This EMV certification is expected to help acquirers to remain compliant with the Central Bank of Philippines (BSP) regulation.”
About MOBI724
MOBI724, a leader in the fintech industry based in Montreal (Canada), offers a unique and fully integrated suite of payment & digital marketing solutions with a combined EMV Payment, Card Linked Offers, and Digital Marketing platform that works on any card and any Mobile device. MOBI724’s solutions add value to all types of transactions benefiting banks, retailers and cardholders by leveraging available user and purchasing data to increase transaction volumes and spend. MOBI724 provides a turnkey solution to its clients to capture card transactions on any Mobile device, at any point of sale or from any payment card. MOBI724 provides its customers with full and comprehensive traceability and enriched consumer data through its offering. Its solutions enables card associations, retailers, manufacturers, offer providers, Mobile operators and card issuers to create, manage, deliver and “track and measure” incentive campaigns worldwide to any Mobile device and allow its redemption at any point of sales.
Forward-Looking Statements
Certain statements in this document, including those which express management’s expectations or estimations with regard to the Company’s future performance, constitute “forward-looking statements” as understood by applicable securities laws. Forward-looking statements are, of necessity, based on a certain number of estimates and hypotheses; while management considers these to be accurate at the time they are expressed, they are inherently subject to significant uncertainties and risks on the commercial, economic and competitive levels. We advise readers that these forward-looking statements are subject to risks, uncertainties, and other known and unknown factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied in these forward-looking statements. Investors are advised to not rely unduly on the forward-looking statements. This advisory applies to all forward-looking statements, whether expressed orally or in writing, attributed to the Company or to any individual expressing them in the name of the Company. Unless required by law, the Company is under no obligation to publicly update these forward-looking statements, whether to reflect new information, future events, or other circumstances.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
MOBI724 Global Solutions Inc.
Marcel Vienneau
1-514-394-5200 x 413
www.MOBI724.com
- Published in Financial Technology, Mobi724 Global Solutions, News Home, Technology
Tetra Bio-Pharma: The Canadian Pioneer in Cannabis-Based Pharma for Pain Relief in Cancer Patients
Momentum PR ‘s client, Tetra Bio-Pharma is listed on the Canadian Securities Exchange under the symbol TBP as well as on the OTCQB in the US under the symbol GRPOF
Momentum PR is pleased to have produced an informative and comprehensive report on Tetra Bio-Pharma available on the Momentum PR LinkedIn page.
Tetra Bio-Pharma Highlights:
- – Canadian-based pioneer, innovator and first to market in cannabis-based pharmaceuticals- Global medical marijuana market is estimated to reach US$55.8 billion by 2025- Tetra Bio-Pharma is the first and only bio-pharma company in North-America focused on cannabinoid (CBD) clinical stage pain relief products- Tetra is the only bio-pharma company currently running a double-blind Phase 1 study with organically-grown cannabis
– Positive outcome from trials will result in for North-American Drug Identification Numbers (DIN), thus qualifying prescriptions for insurance coverage.
– Strategic partnership with Aphria Inc. announced in November 2016 and solidified in April 2017
Tetra Bio-Pharma is a Canadian-based pioneer, innovator and first market mover in developing cannabis-based pharmaceuticals. These are used for the treatment of cancer-related pain and the resultant nausea, as well as anorexia and Post Traumatic Stress Disorder (PTSD).
The global medical marijuana market is estimated to reach US$55.8 billion by 2025, according to Grand View Research. Health Canada has stated that they expected a mature medical marijuana market worth C$1.3 billion by 2024 in Canada alone.
Tetra Bio-Pharma is the first and only bio-pharmaceutical company in North-America that is focused on cannabinoid (CBD) clinical stage pain relief products. The Company believes that if all goes well, its flagship drug, PPP001, designed to treat the chronic pain associated with many cancers, will be on the market in 2019. The Canadian Cancer Society is estimating a 35{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} growth rate in cancer cases in Quebec, and 40{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} nationally by 2030. They also advocate for more spending on research on innovative drugs and end-of-life treatment.
Tetra Bio-Pharma is accelerating the acceptance of cannabis-based medical treatments. It is the only bio-pharmaceutical company currently running a double-blind Phase 1 study. It aims to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single and multi-daily ascending doses of cannabis by smoking in healthy volunteers.
Pending a positive outcome, cannabis-based drugs designed to treat cancer pain and nausea from chemotherapy, PTSD and a number of other ailments will qualify for North-American Drug Identification Numbers (DIN). This means that prescriptions would be eligible for insurance coverage.
In addition to developing proprietary products and intellectual property, Tetra Bio-Pharma signed a supply agreement with ACMPR licensed producer Aphria Inc. on November 3, 2016. The Tetra-Aphria partnership was further solidified on April 19, 2017 when plans were announced for the joint distribution of dried medical cannabis for Quebec and the Atlantic Provinces.
The Momentum PR informative and comprehensive report on Tetra Bio-Pharma is available on the Momentum PR LinkedIn page.
If you would like more information on Tetra Bio-Pharma listed on the Canadian Securities Exchange under the symbol TBP with a market cap of C$ 70 million, or would like to arrange an interview with management please contact:
Momentum PR
Juliette Benard, Director Media Relations
+1.450.332.6939
About Momentum PR
Momentum PR is a cutting-edge public and investor relations consulting agency representing companies within the Canadian investment community.
Since 2009, Momentum PR has been servicing small and mid cap Canadian listed public companies, seeking to increase their exposure across North America. The focus at Momentum PR is on building and driving brand awareness. Momentum PR cultivates new audiences in the media and investment communities by proactively engaging interested parties on behalf of client companies through online and offline channels.
Disclaimer:
All editorial content contained herein is solely the responsibility of Momentum PR and does not reflect, in any way, the opinions of TheNewswire.ca Inc., its partner newswires and / or associated news services.
– See more at: The Newswire
- Published in Blog, Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
IWS Announces DC Water Installation
IWS Announces DC Water Installation
VANCOUVER, BRITISH COLUMBIA–(Marketwired – May 2, 2017) – International Wastewater Systems Inc. (“IWS” or the “Company”) (CSE:IWS)(CSE:IWS.CN)(FRANKFURT:IWI)(OTC PINK:INTWF) is pleased to announce that it has been awarded a US$330,000 (CAN$478,000) contract to supply its innovative SHARC thermal energy exchange system to the new headquarters of the District of Columbia Water and Sewer Authority (“DC Water”) in Washington, DC.
The new $60 million headquarters (“DC Water HQ”) is being constructed on the waterfront of the Anacostia River in Southeast Washington, DC and will serve as the new public face for the agency. DC Water’s green initiatives will be showcased in a deeply innovative facility featuring a bold and distinctive design developed by SmithGroupJJR in collaboration with Skanska. The building is designed to achieve LEED Platinum certification from the U.S. Green Building Council and will also employ many advanced strategies that will surpass LEED Platinum certification.
The SHARC system will allow DC Water HQ to use its own wastewater as a source of thermal energy to condition the building. This project represents a historic HVAC first. The DC Water HQ building will be the first ever deployment of this technology used to both heat and cool a building in the USA.
With two-thirds of all the outflow from DC’s sewers flowing through the underground infrastructure on the site, the system will have a virtually uninterruptible supply of thermal energy. Utilizing this technology, the design team has calculated that the DC Water HQ will take its place as one of the lowest energy-consuming office buildings in the region.
“The idea of building a 150,000-square-foot headquarters building directly over a pumping station would normally be viewed as implausible,” said SmithGroupJJR’s Corporate Director of Engineering Don Posson. “But by doing so, DC Water will be able to leverage the station’s wastewater to provide enough power to heat and cool this large building. It’s a breakthrough solution and a perfect complement to DC Water’s objective of a greener, healthier District of Columbia.”
IWS will install the SHARC 440 model with a flow rate of 250 gallons per minute, providing the primary energy source for building heat, and the primary energy rejection source for building cooling. IWS’s SHARC technology is a major contributor to the project’s LEED® Platinum 96 credit threshold, delivering one of the lowest energy consumption rates per unit of floor area possible, while reducing greenhouse gas emissions by over 40{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}, and water consumption by hundreds of thousands of gallons annually.
Lynn Mueller, CEO of IWS commented: “DC Water’s new state-of-the-art building is a world class design-build project. The integration of SHARC technology demonstrates the world-class caliber of IWS’s projects and partners, and represents the increased adoption of IWS systems in the United States.”
ON BEHALF OF THE BOARD
Lynn Mueller, Chairman and Chief Executive Officer
About International Wastewater Systems Inc.
International Wastewater Systems Inc. is a world leader in thermal heat recovery. IWS systems recycle thermal energy from wastewater, generating the most energy efficient and economical systems for heating, cooling & hot water for commercial, residential and industrial buildings. IWS is publicly traded in Canada (CSE:IWS)(CSE:IWS.CN), the United States (OTC PINK:INTWF) and Germany (FRANKFURT:IWI).
Forward-Looking Information
This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.
CONTACT INFORMATION
-
International Wastewater Systems Inc.
Yaron Conforti
CFO and Director
(416) 716 8181
yaron.conforti@iws-sharc.com
- Published in Energy, Green Technology, International Wastewater Systems, News Home, Technology
Mobi724 Global Solutions Inc. Announces Closing of Private Placement Offering for Gross Proceeds of over 10M
Mobi724 Global Solutions Inc. Announces Closing of Private Placement Offering for Gross Proceeds of over 10M
Momentum Public Relations
Press Release: April 21, 2017
Mobi724 Global Solutions Inc. (“Mobi724” or the “Company”) (CSE:MOS)(CSE:MOS.CN) – a Fintech leader offering all in one fully integrated EMV payment, card link couponing and digital marketing solutions, announces that it has successfully completed its private placement offering of special warrants (the “Special Warrants”), previously announced by news releases dated April 4, and April 6, 2017, issuing an aggregate of 29,538,203 Special Warrants at a price of $0.35 per Special Warrant for aggregate gross proceeds of $10,338,371.05, which includes the exercise by GMP Securities L.P. (“GMP”), as sole lead agent, of its option for an additional 2,395,346 Special Warrants.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
For more information, please visit www.mobi724globalsolutions.com.
About Mobi724 Global Solutions
Mobi724, a leader in the fintech industry based in Montreal (Canada), offers a unique and fully integrated suite of payment & digital marketing solutions with a combined EMV Payment, Card Linked Offers, and Digital Marketing platform that works on any card and any mobile device. Mobi724’s solutions add value to all types of transactions benefiting banks, retailers and cardholders by leveraging available user and purchasing data to increase transaction volumes and spend. Mobi724 provides a turnkey solution to its clients to capture card transactions on any mobile device, at any point of sale or from any payment card. Mobi724 provides its customers with full and comprehensive traceability and enriched consumer data through its offering. Its solutions enables card associations, retailers, manufacturers, offer providers, mobile operators and card issuers to create, manage, deliver and “track and measure” incentive campaigns worldwide to any mobile device and allow its redemption at any point of sales.
Forward Looking Statements
Certain statements in this document, including those which express management’s expectations or estimations with regard to the Company’s future performance, constitute “forward-looking statements” as understood by applicable securities laws. Forward-looking statements are, of necessity, based on a certain number of estimates and hypotheses; while management considers these to be accurate at the time they are expressed, they are inherently subject to significant uncertainties and risks on the commercial, economic and competitive levels. We advise readers that these forward-looking statements are subject to risks, uncertainties, and other known and unknown factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied in these forward-looking statements. Investors are advised to not rely unduly on the forward-looking statements. This advisory applies to all forward-looking statements, whether expressed orally or in writing, attributed to the Company or to any individual expressing them in the name of the Company. Unless required by law, the Company is under no obligation to publicly update these forward-looking statements, whether to reflect new information, future events, or other circumstances.
The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
MOBI724 Global Solutions Inc.
Marcel Vienneau
1-514-394-5200 x 413
www.mobi724globalsolutions.com
© 2017 Canjex Publishing Ltd. All rights reserved.
- Published in Financial Technology, Mobi724 Global Solutions, News Home, Technology